z-logo
Premium
Effect of supplemented sericin on the development, cell number, cryosurvival and number of lipid droplets in cultured bovine embryos
Author(s) -
Hosoe Misa,
Inaba Yasushi,
Hashiyada Yutaka,
Imai Kei,
Kajitani Kenji,
Hasegawa Yuichi,
Irie Mamoru,
Teramoto Hidetoshi,
Takahashi Toru,
Niimura Sueo
Publication year - 2017
Publication title -
animal science journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.606
H-Index - 38
eISSN - 1740-0929
pISSN - 1344-3941
DOI - 10.1111/asj.12628
Subject(s) - sericin , blastula , embryo , andrology , blastocyst , fetal bovine serum , chemistry , in vivo , in vitro , embryogenesis , biology , biochemistry , microbiology and biotechnology , materials science , silk , medicine , gastrulation , composite material
Abstract Sericin was investigated as an alternative to fetal bovine serum (FBS) for bovine embryo culture. In vitro matured oocytes were developed using 0.05%, 0.1% or 0.15% sericin. The developmental rate, cryosurvival rate and blastulation time of these embryos were compared with those of embryos developed using 5% FBS. The number of lipid droplets was compared among the blastocysts developed using 5% FBS, using 0.05% sericin and in vivo . The rate of cleavage and blastocyst formation was similar among all groups. Blastulation occurred significantly earlier in the embryos developed using 5% FBS than in those developed using sericin at any concentration ( P  < 0.05). At 72 h after thawing, the cryosurvival rate of the blastocysts developed using 5% FBS and 0.05% sericin were significantly higher compared with those developed using 0.1% and 0.15% sericin ( P  < 0.05). The blastocysts developed using 0.05% sericin and in vivo produced a significantly fewer number of medium and large lipid droplets than those developed using 5% FBS. These results suggest that the blastocysts developed using 0.05% sericin show characteristics similar to those of the blastocysts developed in vivo and that the use of sericin as an alternative to FBS is feasible.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here